Comparative Pharmacology
Head-to-head clinical analysis: TELMISARTAN AND AMLODIPINE versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TELMISARTAN AND AMLODIPINE versus TEVETEN HCT.
TELMISARTAN AND AMLODIPINE vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Oral: one tablet containing telmisartan 40-80 mg and amlodipine 5-10 mg once daily; maximum dose: telmisartan 80 mg/amlodipine 10 mg daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Telmisartan: terminal half-life ~24 hours (range 20-30 hours), supporting once-daily dosing. Amlodipine: terminal half-life ~30-50 hours (mean 35 hours), achieving steady state after 7-8 days; prolonged half-life allows once-daily dosing.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Telmisartan: primarily excreted unchanged in feces (97%) via biliary elimination; renal excretion accounts for <2%. Amlodipine: extensively metabolized in liver; 60% of metabolites excreted renally, 20-25% in feces. Unchanged amlodipine in urine: <10%.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination